Real‐world weight‐loss effectiveness of glucagon‐like peptide‐1 agonists among patients with type 2 diabetes: A retrospective cohort study
Authors' conclusion
In this real-world study of more than 2400 patients with overweight or obesity and type 2 diabetes, starting a GLP-1 agonist at standard glycemic control doses was associated with modest weight loss through 72 weeks.
Study context
- Population
- Nonpregnant adults with T2D first dispensed a GLP-1 agonist (2011–2018), large health system; mean age 48 (SD 10) years, 53% female, mean BMI 37 (8) kg/m², mean baseline weight 238 (54) lb
- Participants
- 2,405 adults
- Outcome
- Percent change in body weight after starting a GLP-1 agonist
- Follow-up
- 72 weeks
Methodological detailselectronic health record data, linear mixed models with person-level random intercept
- Electronic health record data
- Linear mixed models with person-level random intercept
Main finding
As reported in the abstract
Mean percent weight loss
GLP-1 agonist
2.2%
mean · 95% CI 1.7%–2.6%
- Mean percent weight loss significantly increased from 8 to 72 weeks after dispensing
- p value for quadratic trend < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Mean percent weight loss · 8 weeks | GLP-1 agonist mean 1.1% (95% CI 0.6%–1.6%) |
Weight loss ≥5% · 72 weeks
- Patients who lost ≥5% body weight
- One-third
Original publication
Real‐world weight‐loss effectiveness of glucagon‐like peptide‐1 agonists among patients with type 2 diabetes: A retrospective cohort study. Obesity (Silver Spring). Published 9 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →